Associations between surveillance of serum urate levels within 6 months of initiating a urate-lowering drug (ULD) and sex, comorbidities, gout treatments and number of ULD dispensings
| Factor | Unadjusted | Adjusted* | ||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| NSAID, non-steroidal anti-inflammatory drug; ULD, urate-lowering drug. | ||||
| *Controlled for individual Health maintenance organizations as well as the above-mentioned variables. | ||||
| Sex (men referent) | 1.49 | 1.23 to 1.80 | 1.36 | 1.11 to 1.67 |
| Dyslipidaemia | 1.65 | 1.40 to 1.93 | 1.42 | 1.19 to 1.68 |
| Renal insufficiency | 1.97 | 1.57 to 2.48 | 1.74 | 1.35 to 2.23 |
| Colchicine use | 1.80 | 1.54 to 2.10 | 1.61 | 1.36 to 1.90 |
| Glucocorticoid use | 1.82 | 1.52 to 2.17 | 1.56 | 1.29 to 1.89 |
| Selective NSAID use | 2.35 | 1.67 to 3.51 | 1.76 | 1.15 to 2.70 |
| Non-selective NSAID use | 1.39 | 1.19 to 1.63 | 1.62 | 1.37 to 1.92 |
| ULD (number of dispensings; one dispensing referent) | ||||
| Two | 1.42 | 1.07 to 1.88 | 1.65 | 1.23 to 2.22 |
| Three | 1.72 | 1.32 to 2.24 | 2.15 | 1.63 to 2.84 |
| Four | 1.95 | 1.48 to 2.56 | 2.25 | 1.68 to 3.00 |
| Five | 2.46 | 1.79 to 3.38 | 2.27 | 1.63 to 3.18 |
| Six or more | 2.42 | 1.84 to 3.19 | 2.37 | 1.77 to 3.18 |